ITEMS IN AFP WITH KEYWORD:
In an extremely high-risk group of patients with known vascular disease, taking evolocumab instead of placebo in addition to standard statin therapy for slightly more than two years will prevent one myocardial infarction (MI) for every 83 persons treated and prevent one stroke for every 250 persons treated.
What are the effects of treatments for venous leg ulcers? What are the effects of various interventions for venous leg ulcers?
Jan 15, 2017 Issue
Giant Cell Arteritis: Biopsy After Corticosteroid Initiation [FPIN's Clinical Inquiries]
Corticosteroid therapy in patients with suspected giant cell arteritis should not degrade the accuracy of temporal artery biopsy if the biopsy is performed within four weeks of corticosteroid initiation. Temporal artery biopsy can be performed up to four weeks after starting high-dose corticosteroid therapy.
Mar 15, 2016 Issue
American Academy of Pediatrics Releases Report on Infantile Hemangiomas [Practice Guidelines]
The American Academy of Pediatrics has published a report to provide an update on diagnosing and managing infantile hemangiomas.
A woman with systemic lupus erythematosus had pain in her hands and discoloration on the tips of her fingers and toes when exposed to cold.
Vorapaxar should be limited to select patients with a history of MI or peripheral arterial disease who desire additional treatment for the prevention of MI.
A woman presented with gradually decreasing vision in her right eye. Retinal examination revealed intraretinal hemorrhages in the right eye with edema.
This large, adequately powered trial did not find any clinically meaningful benefit to the use of niacin in patients who are already taking a statin, even with several study design features that should bias the result in favor of niacin. Niacin should not be prescribed to reduce the risk of cardiova...
What are the effects of drug treatments for primary Raynaud phenomenon?
Aug 1, 2014 Issue
Effectiveness of Calcium Channel Blockers for Raynaud Phenomenon [Cochrane for Clinicians]
CCBs are modestly effective at reducing the frequency of attacks of primary Raynaud phenomenon. There is no evidence that attack severity or physiologic measurements are reduced by CCBs. Treatment is associated with adverse effects such as headache, flushing, and edema.